Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited (TEVJF) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for Teva Pharmaceutical Industries Limited (TEVJF), featuring income statements, balance sheets, and cash flow data.
Teva Pharmaceutical Industries Limited (TEVJF) Income Statement & Financial Overview
View the income breakdown for Teva Pharmaceutical Industries Limited TEVJF across both annual and quarterly reports.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $3.89B | $4.23B | $4.33B | $4.16B |
| Cost of Revenue | $2.01B | $2.11B | $2.18B | $2.14B |
| Gross Profit | $1.88B | $2.12B | $2.15B | $2.02B |
| Gross Profit Ratio | $0.48 | $0.50 | $0.50 | $0.49 |
| R&D Expenses | $247.00M | $247.00M | $240.00M | $279.00M |
| SG&A Expenses | $919.00M | $952.00M | $924.00M | $939.00M |
| Operating Expenses | $1.36B | $2.15B | $2.20B | $2.03B |
| Total Costs & Expenses | $3.37B | $4.26B | $4.38B | $4.17B |
| Interest Income | $0.00 | -$48.00M | $0.00 | $0.00 |
| Interest Expense | $225.00M | $239.00M | $272.00M | $241.00M |
| Depreciation & Amortization | $244.00M | $269.00M | $259.00M | $259.00M |
| EBITDA | $763.00M | $261.00M | $207.00M | $254.00M |
| EBITDA Ratio | $0.20 | $0.06 | $0.05 | $0.06 |
| Operating Income | $519.00M | -$29.00M | -$51.00M | -$5.00M |
| Operating Income Ratio | $0.13 | -$0.007 | -$0.01 | -$0.001 |
| Other Income/Expenses (Net) | -$225.00M | -$218.00M | -$273.00M | -$240.00M |
| Income Before Tax | $294.00M | -$247.00M | -$324.00M | -$245.00M |
| Income Before Tax Ratio | $0.08 | -$0.06 | -$0.07 | -$0.06 |
| Income Tax Expense | $74.00M | $28.00M | $69.00M | $630.00M |
| Net Income | $214.00M | -$217.00M | -$437.00M | -$846.00M |
| Net Income Ratio | $0.05 | -$0.05 | -$0.10 | -$0.20 |
| EPS | $0.19 | -$0.19 | -$0.39 | -$0.75 |
| Diluted EPS | $0.18 | -$0.19 | -$0.39 | -$0.75 |
| Weighted Avg Shares Outstanding | $1.14B | $1.13B | $1.13B | $1.13B |
| Weighted Avg Shares Outstanding (Diluted) | $1.16B | $1.13B | $1.13B | $1.13B |
Financial performance has remained strong, with revenue growing from $4.16B in Q2 2024 to $3.89B in Q1 2025. Gross profit continued to perform well, with margins at 48% in the latest quarter. Operating income reached $519.00M in Q1 2025, holding a steady 13% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $763.00M. Net income rose to $214.00M, keeping EPS at $0.19. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan